Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Income towards Parent Company (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Income towards Parent Company for 9 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company rose 31.92% year-over-year to $17.0 million, compared with a TTM value of $35.2 million through Dec 2025, up 50.01%, and an annual FY2024 reading of $24.1 million, up 2325.3% over the prior year.
  • Income towards Parent Company was $17.0 million for Q4 2025 at Puma Biotechnology, up from $9.1 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $20.0 million in Q3 2024 and bottomed at -$44.7 million in Q3 2021.
  • Average Income towards Parent Company over 5 years is $2.1 million, with a median of $3.5 million recorded in 2021.
  • The sharpest move saw Income towards Parent Company skyrocketed 1531.11% in 2023, then plummeted 443.68% in 2024.
  • Year by year, Income towards Parent Company stood at $4.1 million in 2021, then skyrocketed by 75.99% to $7.3 million in 2022, then tumbled by 243.41% to -$10.4 million in 2023, then surged by 223.57% to $12.9 million in 2024, then skyrocketed by 31.92% to $17.0 million in 2025.
  • Business Quant data shows Income towards Parent Company for PBYI at $17.0 million in Q4 2025, $9.1 million in Q3 2025, and $6.2 million in Q2 2025.